Formulation And In Vitro Evaluation Of Sustained-Release Canagliflozin Nano-Particles For The Treatment Of Diabetic
Keywords:
Canagliflozin, Sustained-release, Nanoparticles, enhance patient complianceAbstract
The development of sustained-release Canagliflozin (CFZ) nanoparticles marks a significant advancement in the management of type 2 diabetes mellitus, particularly for patients requiring long-term glycemic control. This study meticulously evaluated the physicochemical properties, in vitro drug release profiles, and stability of CFZ-loaded nanoparticles, aiming to enhance therapeutic efficacy and patient compliance. In summary, the development of CFZ nanoparticles, along with the utilization of polymeric nanoparticles and stimuli-responsive systems, represents a promising strategy to enhance the oral bioavailability and therapeutic efficacy of this poorly soluble drug. These advancements in drug delivery technologies hold significant potential for improving the treatment of conditions such as diabetes.
Downloads
Metrics
References
Piñón-Segundo, E., Llera-Rojas, V.G., Leyva-Gómez, G., Urbán-Morlán, Z., Mendoza-Muñoz, N. and Quintanar-Guerrero, D., 2018. The emulsification-diffusion method to obtain polymeric nanoparticles: Two decades of research. Nanoscale fabrication, optimization, scale-up and biological aspects of pharmaceutical nanotechnology, pp.51-83.
Moideen, S.M. and Kuppuswamy, S., 2014. Significance of nanoparticle drug delivery system than conventional drug delivery system of antihypertensive drugs. World Journal of Pharmaceutical Research, 3(4), pp.995-1019.
Yellela S.R. Krishnaiah, Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs, JBB, Volume 2(2), (2010) – 029, 028-036.
Sanjay Singh, Ajay Kumar Dobhal, Achint Jain, Jayant Kumar Pandit, And Subhashis Chakraborty, Formulation And Evaluation Of Solid Lipid Nanoparticles Of A Water Soluble Drug: Zidovudine, Chem. Pharm. Bull, 2010, 58(5) 650—655.
Akl MA, Kartal-Hodzic A, Oksanen T, et al. Factorial design formulation optimization and in vitro characterization of curcumin-loaded PLGA nanoparticles for colon delivery. J Drug Deliv Sci Technol 2016; 32:10-20.
Lokhande A, Mishra S, Kulkarni R, Naik J. Formulation and evaluation of glipizide loaded nanoparticles. J Pharm Pharm Sci 2013; 5: 147-51.
Wang Y, Wang C, Zhao J, Ding Y, and Li L, Journal of Colloid and Interface Science A cost-effective method to prepare curcumin nanosuspensions with enhanced oral bioavailability,J. Colloid Interface Sci., 2017, 485: 91–98.
Sperling, R. A., & Dähne, L. (2010). "Functionalized nanoparticles." Materials Today, 13(8-9), 52-59. https://doi.org/10.1016/S1369-7021(10)70176-9
Shah P., Chavda K., Vyas B., Patel S. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Deliv Transl Res. 2021;11: 1166-1185.
Dhome A., Deshkar S., Shirolkar S. Gliclazide solid lipid nanoparticles: Formulation, Pharmaceutical Resonance. 2018;1:8-16.
Navaneetha K., Navya A., Reddy V.B. et el. Formulation and in-vitro evaluation of nanoparticles of linagliptin. World J Pharm Res. 2017;6: 1319-1328.
Sawant, A., Kamath, S., Kg, H. and Kulyadi, G.P., 2021. Solid-in-oil-in-water emulsion: an innovative paradigm to improve drug stability and biological activity. AAPS PharmSciTech, 22, pp.1-14.
Dr.M. Sunitha Reddy; N. Sowjanya, “Formulation and in-vitro Characterization of Solid Self Nanoemulsifying Drug Delivery System (s- SNEDDS) of Simvastatin”, J. Pharm. Sci. & Res. Vol. 7(1), 2015, 40-48.
Gonullu, Umit, Uner, Melike, Yener, Gulgun Karaman, Ecem Fatma, “Formulation and characterization of solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsion of lornoxicam for transdermal delivery, Acta pharmaceutica PMId 25781700.
Nidhi Aggarwal and Shishu Goindi, “Preparation and In Vivo Evaluation of Solid Lipid Nanoparticles of Griseofulvin for Dermal Use” Journal of Biomedical Nanotechnology Vol. 9, 564–576, 2013.
Rabea Parveen, F. J. Ahmad, Z. Iqbal, M. Samim & Sayeed Ahmad (2014) Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies, Drug Development and Industrial Pharmacy, 40:9, 1206-1212.
Anand Kumar Kushwaha, Parameswara Rao Vuddanda, Priyanka Karunanidhi, Sanjay Kumar Singh, and Sanjay Singh, “Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability”, BioMed Research International Volume 2013 (2013), Article ID 584549.
Prakash S, formulation and evaluation of herbal anti-acne gel Journal of Pharmaceutical Negative Results ¦ Volume 13 ¦ Special Issue 6 2022.
Prakash S, To Study the Antiulcer Activity of Hydro Alcoholic Extract of Euphorbia Thymifolia on Absolute Ethanol Induced Ulcer in Rats. European Journal of Molecular & Clinical Medicine ISSN 2515-8260 Volume 10, Issue 1 2023.
Prakash S, et. Al., 2022 Guidelines for Approval of Clinical Trials and Study Reports of SARS Covid-19 Vaccines. IJPRA, ISSN: 2456-4494. 64.
Satya Prakash, et. Al., 2023 Gold Nanoparticles for Targeted and Selective Delivery of Cancer Chemotherapeutics: A Review of the Literature (Eur. Chem. Bull. 2023, 12 (Special Issue 1), 2896-2901).
Prakash S, et. Al., Formulation and Evaluation of Floating Tablet Zolmitriptan. (International Journal of Advanced Science and Technology Vol. 28 No. 17 (2019): Vol 28 No 17 (2019))
Prakash S, Tyagi P, Singh P, Rajkumar, Singh AP. Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions. Curr Cancer Drug Targets. 2024 Oct 25. doi: 10.2174/0115680096331827240911165227. Epub ahead of print. PMID: 39473111.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
